Literature DB >> 5904980

Relative importance of formiminoglutamic and urocanic acid excretion after a histidine load.

S D Mohamed, M Roberts.   

Abstract

A thin-layer chromatographic method for the simultaneous assessment of formimino-glutamic (Figlu) and urocanic acid excretion after loading with 15 g. histidine has been applied to 15 control subjects and to 49 selected patients. Upper limits of normal excretion were determined for urocanic acid and Figlu alone (15 mg. and 30 mg/8 hr. respectively), and for the combined metabolites (40 mg./8 hr.). Of the 49 patients studied, 27 excreted total metabolites above 40 mg./8 hr.; of these 19 would have been revealed by their abnormal excretion of Figlu and 22 by their abnormal excretion of urocanic acid. Of 74 tests in the 64 subjects, urocanic acid was present in all but 27% of the tests, and in 29.8% of the tests urocanic acid was in excess of the amount of Figlu excreted. In six normal and six abnormal tests urocanic acid was the sole metabolite present. These results re-emphasize the value of estimating both histidine metabolites in tests for folate deficiency in man, and underline the greater relative importance of urocanic acid.

Entities:  

Mesh:

Substances:

Year:  1966        PMID: 5904980      PMCID: PMC473155          DOI: 10.1136/jcp.19.1.37

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  23 in total

1.  Histidine metabolic loading test to distinguish folic acid deficiency from vit. B12 in megaloblastic anemias.

Authors:  A L LUHBY; J M COOPERMAN; D N TELLER
Journal:  Proc Soc Exp Biol Med       Date:  1959-06

2.  ABNORMAL URINARY EXCRETION OF UROCANIC ACID AND FORMIMINOGLUTAMIC ACID IN NEOPLASTIC DISEASE.

Authors:  I W DYMOCK
Journal:  Lancet       Date:  1964-07-18       Impact factor: 79.321

3.  URINARY FORMIMINOGLUTAMIC ACID EXCRETION IN PATIENTS WITH NEOPLASTIC DISEASE.

Authors:  R W CAREY; G P BRENA; M J KRANT
Journal:  Cancer       Date:  1964-06       Impact factor: 6.860

4.  Urinary excretion of urocanic acid and formimino-glutamic acid.

Authors:  M C BENNETT; I CHANARIN
Journal:  Nature       Date:  1962-10-20       Impact factor: 49.962

5.  Abnormal folic acid metabolism in vitamin B12 deficiency.

Authors:  J P KNOWLES; T A PRANKERD
Journal:  Clin Sci       Date:  1962-04       Impact factor: 6.124

6.  The metabolism of histidine. II. Effects of folic acid deficiency.

Authors:  R C BALDRIDGE
Journal:  J Biol Chem       Date:  1958-03       Impact factor: 5.157

7.  Some constituents of the urine of normal and schizophrenic individuals.

Authors:  R M ACHESON; R M PAUL; R V TOMLINSON
Journal:  Can J Biochem Physiol       Date:  1958-03

8.  Folic-acid-excretion studies in the investigation of malignant disease.

Authors:  R H GIRDWOOD
Journal:  Br Med J       Date:  1953-10-03

9.  The nutritional status of folic acid in persons with leukemia and its possible relation to effects of aminopterin therapy.

Authors:  M E SWENDSEID; A L SWANSON; M C MEYERS; F H BETHELL
Journal:  Blood       Date:  1952-03       Impact factor: 22.113

10.  Influence of succinylsulfathiazole and folic acid on glutamic acid excretion.

Authors:  H A BAKERMAN; M SILVERMAN; F S DAFT
Journal:  J Biol Chem       Date:  1951-01       Impact factor: 5.157

View more
  3 in total

1.  Urinary excretion of 3-hydroxyisovaleric acid and 3-hydroxyisovaleryl carnitine increases in response to a leucine challenge in marginally biotin-deficient humans.

Authors:  Donald M Mock; Shawna L Stratton; Thomas D Horvath; Anna Bogusiewicz; Nell I Matthews; Cindy L Henrich; Amanda M Dawson; Horace J Spencer; Suzanne N Owen; Gunnar Boysen; Jeffery H Moran
Journal:  J Nutr       Date:  2011-09-14       Impact factor: 4.798

Review 2.  Significance of subnormal red-cell folate in thalassaemia.

Authors:  S C Tso
Journal:  J Clin Pathol       Date:  1976-02       Impact factor: 3.411

3.  Nature of anaemia in rheumatoid arthritis. IX. Folate metabolism in patients with rheumatoid arthritis.

Authors:  A Omer; A G Mowat
Journal:  Ann Rheum Dis       Date:  1968-09       Impact factor: 19.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.